Roivant Sciences Ltd.(ROIV)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,890 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
ROIV Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Roivant Sciences Ltd. (ROIV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ROIV at 12.0/100 on a 32-signal composite quality model, placing it at rank #2,890 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Roivant Sciences Ltd. reports quarterly revenue of $1.4M, net income of $-189.8M, free cash flow of $-270.9M. Top institutional holders of ROIV by reported 13-F value include FMR, BlackRock, MORGAN STANLEY, based on the most recent SEC filings. ROIV trades on the Nasdaq exchange and files with the SEC under CIK 1635088. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ROIV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Roivant Sciences Ltd. directly from SEC EDGAR. Roivant Sciences Ltd.'s 13F Pro composite quality score has ranged between 7 and 43 since 2022, currently 12.0 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.
Revenue
Q2 2026
$1.4M
Net Income
Q2 2026
$-189.8M
Free Cash Flow
Q2 2026
$-270.9M
ROIC
Q2 2026
-34.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-71.6% YoYNet Income
-74.3% YoYOperating Income
+48.7% YoYEPS (Diluted)
-125.0% YoYTotal Assets
+5.0% YoYTotal Debt
Op. Cash Flow
+10.6% YoYFree Cash Flow
+10.1% YoY| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $8.3M -71.6% | $29.1M -11.2% | $32.7M +3.8% | $31.5M -43.0% | $55.3M +132.3% | $23.8M |
| Net Income | $-299.8M -74.3% | $-172.0M -104.0% | $4.35B +531.0% | $-1.01B -19.4% | $-845.3M -4.5% | $-809.2M |
| Operating Income | $-515.1M +48.7% | $-1.00B -122.3% | $4.50B +595.9% | $-906.8M +32.9% | $-1.35B -26.2% | $-1.07B |
| EPS (Diluted) | $-0.54 -125.0% | $-0.24 -104.6% | $5.23 +468.3% | $-1.42 -12.7% | $-1.26 | — |
| Total Assets | $5.71B +5.0% | $5.44B -24.7% | $7.22B +202.2% | $2.39B -7.6% | $2.59B -0.2% | $2.59B |
| Total Debt | — | — | $442.6M +6.3% | $416.2M +98.2% | $210.0M +23.3% | $170.3M |
| Operating Cash Flow | $-750.3M +10.6% | $-839.5M -9.7% | $-765.3M +9.3% | $-843.4M -24.4% | $-677.7M -22.7% | $-552.1M |
| Free Cash Flow | $-758.6M +10.1% | $-844.0M -10.1% | $-766.6M +10.4% | $-856.1M -23.1% | $-695.2M -24.6% | $-557.9M |
Get alerted when ROIV's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Roivant Sciences Ltd. including:
Top Institutional Holders of ROIV
FMR LLC
$2.9B81,020,390 shBlackRock, Inc.
$1.7B48,236,091 shMORGAN STANLEY
$1.5B42,592,905 shQVT Financial LP
$839.6M23,723,074 shVANGUARD CAPITAL MANAGEMENT LLC
$782.9M22,123,198 shVANGUARD PORTFOLIO MANAGEMENT LLC
$765.9M21,641,339 shGOLDMAN SACHS GROUP INC
$656.7M18,556,458 shSTATE STREET CORP
$629.8M17,795,975 shUBS Group AG
$618.1M17,466,641 shFARALLON CAPITAL MANAGEMENT LLC
$506.4M14,309,000 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $2.9B | 81,020,390 |
| BlackRock, Inc. | $1.7B | 48,236,091 |
| MORGAN STANLEY | $1.5B | 42,592,905 |
| QVT Financial LP | $839.6M | 23,723,074 |
| VANGUARD CAPITAL MANAGEMENT LLC | $782.9M | 22,123,198 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $765.9M | 21,641,339 |
| GOLDMAN SACHS GROUP INC | $656.7M | 18,556,458 |
| STATE STREET CORP | $629.8M | 17,795,975 |
| UBS Group AG | $618.1M | 17,466,641 |
| FARALLON CAPITAL MANAGEMENT LLC | $506.4M | 14,309,000 |
Companies Similar to ROIV
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Celldex Therapeutics, Inc.
Arcus Biosciences, Inc.
Dianthus Therapeutics, Inc. /DE/
NewAmsterdam Pharma Co N.V.
Arbutus Biopharma Corp
Absci Corp
NEKTAR THERAPEUTICS
C4 Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ROIV on your watchlist
Track score changes the day Roivant Sciences Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ROIV a good stock to buy?
13F Pro's AI-powered analysis of Roivant Sciences Ltd. (ROIV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ROIV are available on the ROIV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ROIV is classified as a large company.
Which hedge funds own ROIV?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ROIV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Roivant Sciences Ltd.'s investment landscape.